Today: Today, California State Teachers Retirement System invests in Entellus Medical Inc. (ENTL) Shares

Today, California State Teachers Retirement System invests in Entellus Medical Inc. (ENTL) Shares

California State Teachers Retirement System increased its stake in Entellus Medical Inc. (NASDAQ:ENTL) by 36.0% during the second quarter, Holdings Channel reports. The institutional investor owned 15,717 shares of the medical technology company’s stock after buying an additional 4,160 shares during the period. California State Teachers Retirement System owned 0.08% of Entellus Medical worth $287,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in ENTL. Murphy Michael R raised its stake in shares of Entellus Medical by 810.2% in the first quarter. Murphy Michael R now owns 482,137 shares of the medical technology company’s stock valued at $8,770,000 after buying an additional 429,166 shares in the last quarter. State Street Corp increased its position in shares of Entellus Medical by 7.9% in the first quarter. State Street Corp now owns 50,773 shares of the medical technology company’s stock valued at $923,000 after buying an additional 3,714 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Entellus Medical by 8.2% in the first quarter. Geode Capital Management LLC now owns 41,648 shares of the medical technology company’s stock valued at $757,000 after buying an additional 3,160 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Entellus Medical by 19.6% in the second quarter. Bank of New York Mellon Corp now owns 30,307 shares of the medical technology company’s stock valued at $554,000 after buying an additional 4,960 shares during the last quarter. Finally, Eqis Capital Management Inc. increased its position in shares of Entellus Medical by 60.2% in the second quarter. Eqis Capital Management Inc. now owns 26,368 shares of the medical technology company’s stock valued at $482,000 after buying an additional 9,912 shares during the last quarter. Hedge funds and other institutional investors own 66.22% of the company’s stock.

Shares of Entellus Medical Inc. (NASDAQ:ENTL) traded up 0.10% during mid-day trading on Tuesday, hitting $20.40. 10,352 shares of the stock traded hands. The stock’s market cap is $384.52 million. Entellus Medical Inc. has a 12-month low of $13.72 and a 12-month high of $22.63. The firm’s 50 day moving average price is $20.16 and its 200-day moving average price is $18.25.

Entellus Medical (NASDAQ:ENTL) last announced its earnings results on Wednesday, August 3rd. The medical technology company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.08. The business earned $18.73 million during the quarter, compared to the consensus estimate of $18.48 million. Entellus Medical had a negative net margin of 33.54% and a negative return on equity of 41.83%. The business’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.15) earnings per share. Analysts predict that Entellus Medical Inc. will post ($1.23) earnings per share for the current year.

ENTL has been the topic of several research reports. Zacks Investment Research raised shares of Entellus Medical from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Monday, August 8th. Canaccord Genuity reissued a “buy” rating and set a $23.00 price objective on shares of Entellus Medical in a research report on Wednesday, June 29th. BTIG Research reissued a “buy” rating on shares of Entellus Medical in a research report on Wednesday, June 29th. Deutsche Bank AG initiated coverage on shares of Entellus Medical in a research report on Thursday, October 6th. They set a “buy” rating and a $26.00 price objective on the stock. Finally, Bank of America Corp. reissued a “buy” rating on shares of Entellus Medical in a research report on Monday, July 18th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $22.75.

In related news, VP Kevin L. Mensink sold 8,100 shares of the company’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $17.63, for a total value of $142,803.00. Following the sale, the vice president now directly owns 8,000 shares of the company’s stock, valued at $141,040. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP James D. Surek sold 10,000 shares of the company’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $18.71, for a total transaction of $187,100.00. Following the completion of the sale, the vice president now directly owns 95,031 shares in the company, valued at $1,778,030.01. The disclosure for this sale can be found here. 9.10% of the stock is currently owned by insiders.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.

Related posts

Leave a Comment